Conference Reports for NATAP

Back

IAS 2023 July 23rd - 26th 12th IAS Conference on HIV Science     Innovations and implementation of long-acting antiretroviral therapy - (08/29/23)   Long-acting PrEP and the potential for resistance - (08/27/23)   Long-acting PrEP: Programmatic considerations for HIV testing - (08/27/23)   HIV testing approaches: Current and new approaches and considerations for long-acting PrEP - (08/27/23)   Fostering cognitive and mental health in people aging and living with HIV while prioritizing the community and lived experience perspectives - (08/18/23)   Venetoclax, alone and in combination with the BH3-mimetic S63845, depletes HIV latently infected cells and delays rebound in humanized mice - (08/15/23)   Transformation of 3 current short-acting HIV drugs, Tenofovir, Lamivudine and Dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics - (08/15/23)   JABS 48 week results: Implementation of long-acting cabotegravir and rilpivirine in vulnerable populations with complex needs - Reported by Jules Levin (08/15/23)   Incident Hypertension Risk in new Tenofovir Alafenamide Disoproxil users for HIV Pre-Exposure Prophylaxis: Analysis of data from an integrated health system in California - (08/15/23)   Association Between Use of Tenofovir Alafenamide for HIV Pre-Exposure Prophylaxis and Statin Initiation in Adults in an Integrated Health System in California - (08/15/23)   Immune activation is associated with low level viremia and noninfectious comorbidities in people living with HIV - (08/15/23)   Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)   Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)   HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)   Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis - (08/14/23)   Long COVID and HIV: Scientific and Biologic Intersections - (08/14/23)   HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)   Low-level viremia as a risk factor for virologic failure in children and adolescents living with HIV - (08/14/23)   Thymosin α1 in restoring immune response in immunological nonresponders - (08/14/23)   Persistent immune alterations in individuals with Long-COVID during a 6-months period - (08/14/23)   Large decrease in the proportion of newly diagnosed HIV-1 infections grouping in large clusters in Spain - (08/14/23)   PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)   PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)   Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV - (08/14/23)   Accelerated biological aging is associated with intestinal barrier permeability and microbial translocation during antiretroviral therapy suppressed HIV infection - (08/14/23)   Plasma derived extracellular vesicles modulate monocyte function in adults with HIV-related cognitive impairment - (08/14/23)   Self-reported noncommunicable disease prevalence among older people living with HIV in Southern Africa - (08/14/23)   Causes of mortality among people living with HIV: preliminary results from a cross-sectional study at 29 health facilities in Uganda - (08/14/23)   CD4+ T lymphocyte recovery and cognitive function in women living with HIV: Cognitive Function WIHS Women: Viral Suppression/Menopause/Diabetes/HCV - (08/14/23)   Determination of causes of deaths by verbal autopsy methods among people living with HIV in Nigeria - (08/14/23)   Sustained aviraemia in the absence of anti-retroviral therapy in male children following in utero vertical HIV transmission - (08/09/23)   The prospect of elimination of HIV transmission through prevention programs - (08/09/23)   Key REPRIEVE Results and the Utility of Statins Among PWH: What Have We Learned? - (08/09/23)   6 Key Aging/ HIV Messages at IAS 2023 - (08/08/23)   Integrating hepatitis C services into ART clinics in low and middle income countries (LMICs) as an approach toward hepatitis C micro-elimination: pilot experience in Nigeria - (08/07/23)   What's new in WHO guidelines ( HIV & hepatitis): innovations, treatment, integration and monitoring. Amplifying HIV Primary Care, Patent-Centered Care - (08/07/23)   The REPRIEVE trial: Developing a cardiovascular disease prevention strategy for people living with HIV - "should be inserted in Guidelines" - (08/07/23)   Unique aspects of cardiovascular disease among women with HIV: Lessons from REPRIEVE - (08/07/23)   Blood pressure control among patients receiving Integrated care for HIV, diabetes and hypertension in primary health care facilities in Tanzania and Uganda - (08/07/23)   The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review (IAS) - (08/07/23)   New antiretrovirals and HIV treatment strategies - Plenary Long-acting technologies: A game changer? - (08/07/23)   Cardiovascular disease among people living with HIV in high- and low-income countries: Can one strategy fit all? "put them in Guidelines globally" - (08/07/23)   Scaling up cervical cancer prevention services among women living with HIV: lessons and experiences from FIKIA+ project in Mwanza, Tanzania - "99% with small & medium lesions were linked to treatment, large lesions 98%, lesions susceptible to cancer: linked to further care/diagnosis 99%" - (08/07/23)   Willingness to access PrEP for adolescent girls and young women seeking emergency contraception at community pharmacies in Uganda - (08/07/23)   Prevalence and risk factors for renal insufficiency among adults living with HIV in Tanzania: results from a cross-sectional study - (08/04/23)   Group-based trajectory modelling to identify patterns and predictors of myocardial strain in people living with HIV: two-year longitudinal follow-up with speckle tracking echocardiography - (08/04/23)   Ambulatory blood pressure abnormalities and its determinants in people living with HIV and AIDS in an African setting - (08/04/23)   DoxyPEP use, acceptability, and associated health behaviors among a multisite sample of men who have sex with men and transgender women IAS - (08/04/23)   Ethical issues regarding the implementation of doxycycline post-exposure prophylaxis - (08/04/23)   Doravirine resistance patterns identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD phase 3 clinical trials - (08/04/23)   Interpretation of Doravirine Resistance by Algorithm in Antiretroviral-Naïve People with HIV in Haiti - (08/04/23)   Incidence of infections across islatravir clinical development programs - (08/04/23)   Islatravir (MK-8591) has no meaningful effect on the pharmacokinetics of atorvastatin and metformin following coadministration - (08/04/23)   Risk of hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia 2016-2020 - Mark Mascolini (08/03/23)   Meningitis B vaccine for prevention of gonorrhoea: What is the evidence? - (08/03/23)   Doxycycline for STI prevention: Current research and future directions - (08/03/23)   Lenacapavir at 2023 IAS -(08/03/23)   A prospective, randomized trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain - Mark Mascolini (08/03/23)   Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)   Sleep Disorder 25% More Likely With Than Without HIV - Mark Mascolini (08/03/23)   Under 2% of San Franciscans With HIV Have All 5 CVD Risk Factors Controlled - Mark Mascolini (08/03/23)   Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/03/23)   NASH or NAFLD Tied to ASCVD-and NASH to Cognitive Impairment-With HIV - Mark Mascolini(08/03/23)   A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young children - (08/03/23)   JAK Inhibitor Ruxolitinib Reverses Immune Dysfunction and Depletes HIV Reservoir - Mark Mascolini (08/03/23)   MEASURING INTRINSIC CAPACITY: A SCREENING TOOL FOR INTEGRATED CARE IN AGEING PEOPLE WITH HIV - (08/03/23)   The identification of intact HIV proviral DNA in human cerebrospinal fluid - (08/03/23)   Anatomic distribution of HIV-infected cells in tissues after long term antiretroviral therapy - (08/03/23)   Psychiatric multimorbidity among people with HIV aged >40 years in low- and middle-income countries in the Sentinel Research Network of IeDEA - (08/03/23)   Antiretroviral treatment as a protective factor for dysplasia and HPV infection in people living with HIV (PLHIV) - (08/02/23)   The effect of unplanned care interruptions on the mortality of adults resuming antiretroviral therapy in South Africa: a survival analysis - Mark Mascolini (08/02/23)   Global Meta-analysis Confirms Suboptimal Retention and HIV Suppression in Drug Users - Mark Mascolini (08/02/23)   Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/02/23)   AGEING WITH HIV (IAS Plenary): Prioritizing person-centred care - (08/02/23)   Gut dysfunction as an independent driver of neuroinflammation in ART-suppressed SIV - (08/02/23)   Aging of brain network connectivity corresponds to cognitive impairment in persons with HIV - (08/02/23)   Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL - (08/02/23)   Vitamin D and calcium intake are associated with bone deficits among adolescents living with HIV in Zambia and Zimbabwe: low bone density higher among HIV+ (10% v 6%) - (08/02/23)   Stigma and poor mental wellbeing: A global community approach to identifying and addressing common barriers to living well with HIV - Gilead Community Board Selects Barriers to Living Well with HIV - (08/02/23)   Disability in people living with HIV (PLWH) in Asia: a prospective multi-centre case-control study: PWH had higher rates of frailty (6.8% v 1.3%), anxiety, stress, polypharmacy (14.7% v 7%), worse mood - men avg age 53+/-10 - (08/02/23)   Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/02/23)   Sedative drug burden is associated with concurrent physical frailty in people aging with HIV in Canada: findings from the Positive Brain Health Now Study (+BHN) - (08/02/23)   Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV - (08/02/23)   Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/01/23)   Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Mark Mascolini (08/01/23)   Preexisting and Post-Baseline Resistance Analyses in Pooled Pediatric Studies of Emtricitabine/Tenofovir Alafenamide (F/TAF)-Based Antiretroviral Therapy - (08/01/23)   Longitudinal Lymphocyte Dynamics in Virologically Suppressed Children With HIV Initiating Single-Tablet Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) - (08/01/23)   Evaluation of Therapeutic Concentrations of Anti-HIV Antibodies 3BNC117/Teropavimab and 10-1074/Zinlirvimab Through PK-PD Modeling and Prediction of the Washout Duration in HIV Cure Studies - (08/01/23)   Evaluation of Cross-Sectional HIV Incidence Recency Testing in Samples from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial - (08/01/23)   Development of the HIV Care Continuum & Beyond Initiative: Key Focus Areas to End HIV in the Asia-Pacific Region - ViiV Community Global Board Selects Focus Areas to Improve Health Outcomes - (08/01/23)   Initial PrEP product choice: results from the HPTN 084 open-label extension - (08/01/23)   Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Bigger Blood Pressure Jump With DTG in 2nd-Line Therapy Trial - Mark Mascolini (08/01/23)   Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (08/01/23)   Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (08/01/23)   Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (08/01/23)   Association between HIV-related factors and hypertension and diabetes among people living with HIV in Cameroon - (08/01/23)   Incident hypertension in adults initiating tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis: analysis of data from an integrated health system in California - (08/01/23)   Cardiovascular Health Among Persons with HIV without Existing Atherosclerotic Cardiovascular Disease (not good) - (08/01/23)   Risk Characteristics, Risk Perception, and Long-Acting PrEP Awareness and Interest Among Black and Hispanic Men in the US: A National Social Media Survey - (08/01/23)   Patient-Reported Outcomes After 12 Months of Maintenance Therapy With CAB + RPV LA Compared With BIC/FTC/TAF in the Phase 3b SOLAR Study - (08/01/23)   Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study - (07/30/23)   Inflammatory Markers After Switching to Cabotegravir + Rilpivirine Long-Acting vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide: Data From the Phase 3b SOLAR Study - (07/30/23)   Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/30/23)   Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results - (07/30/23)   Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Antiretroviral Therapy (ART)-Naive Adolescents Living With HIV-1: DANCE Study Week 96 Results - (07/30/23)   Acceptable Cost of CAB-LA vs TDF/FTC for PrEP in South African Girls, Young Women - Mark Mascolini - (07/30/23)   Impact of GLP-1 receptor agonists on body weight in patients with type 2 diabetes and HIV - (07/29/23)   Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes - (07/29/23)   Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (07/29/23)   96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV - (07/29/23)   Weight Change and Metabolic Assessment of Virologically Suppressed Children With HIV Aged ≥ 2 Years and Weighing 14 to < 25 Kg Who Received a TAF-Containing Regimen - (07/29/23)   Effect on weight changes upon discontinuation of dolutegravir from antiretroviral regimens among persons with HIV who experienced weight gain - (07/29/23)   Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (07/29/23)   Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (07/27/23)   Same-Day PrEP Popular With Adolescent MSM and TGW in Brazil - Mark Mascolini (07/27/23)   Association of HIV pre-exposure prophylaxis (PrEP) use and bacterial sexually transmitted infections (bSTI) among men who have sex with men (MSM) and transgender women (TGW) in HVTN 704/HPTN 085 - (07/27/23)   Initial PrEP product choice: results from the HPTN 084 open-label extension - (07/27/23)   Positive Predictive Value of HIV Serological Tests in HPTN 084 Trial - (07/27/23)   Acceptability of CAB-LA in cisgender female adolescents in South Africa, Uganda, and Zimbabwe (HPTN 084-01) - (07/27/23)   High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19 - (07/27/23)   Doxycycline post-exposure prophylaxis for STIs: Time for implementation? - (07/27/23)   Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/27/23)   A Prospective, Randomized Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain - (07/27/23)   Risks of hypertension with first-line dolutegravir and tenofovir alafenamide in the NAMSAL and ADVANCE trials - (07/27/23)   Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND - (07/27/23)   Routine Hypertension Rx Nearly Erases Blood Pressure Disadvantage With DTG (mediated by weight gain) - Mark Mascolini (07/27/23)   Prior M184V/I and Multiple Prior Virological Failures Have No Impact on the Efficacy of Switching HIV+ Adults to DTG/3TC Through 96Wks in SOLAR-3D - (07/27/23)   Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)   High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial. - Mark Mascolini (07/27/23)   Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75 mg) once daily: week 48 results from 2 randomized, active-controlled Phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)   Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23)   Feasibility, Acceptability, and Preliminary Efficacy of LifeSteps for PrEP for Youth Pilot Study (ATN 158) - Fenway Clinic Boston USA - (07/27/23)   Implementation of Doxycycline Post-Exposure Prophylaxis to Prevent Sexually Transmitted Infections at a Frontline Boston Community Health Center - (07/27/23)   Initiation of pre-exposure prophylaxis (PrEP) among key populations in PEPFAR-supported countries during 2019-2022 - not good - (07/27/23)   PrEP Use Up in Australian MSM With Regular Partners- Especially if They Also Have Casual Partners - Mark Mascolini (07/27/23)   Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/27/23)   Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents - (07/26/23)   Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/26/23)   No Rebound 20 Months After ART Stops After Novel Stem Cell Transplant - Mark Mascolini (07/26/23)   Evaluation of Incident Hypertension and Blood Pressure Changes Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks - (07/26/23)   Dapivirine vaginal ring (DPV-R): An acceptable and feasible HIV prevention option. Evidence from Zimbabwe? - (07/26/23)   HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 - (07/26/23)   High rate of hepatitis C and reinfection after direct-acting antiviral treatment among men-who-have-sex-with-men living with HIV in Bangkok, Thailand - (07/26/23)   Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered - (07/26/23)   Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/26/23)   Comparison of Long-Acting Lenacapavir Phase 2/3 Regimen vs Simplified Regimen Using Population-PK Analysis and Simulation - (07/26/23)   Recommendations for Missed Oral Lenacapavir Loading Doses Using Population-Pharmacokinetics-Based Simulations - (07/26/23)   Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study - (07/26/23)   Switching to Dolutegravir/Lamivudine (DTG/3TC) Is Non-inferior to Continuing Tenofovir Alafenamide (TAF)-Based Regimens at Week 196: TANGO Subgroup Analyses - (07/26/23)   Pharmacokinetics (PK), Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Pregnant Women With HIV - (07/26/23)   People living with HIV not more likely to be hospitalized with mpox unless immunosuppressed, finds WHO analysis - (07/25/23)   Cancer drug shows promise in HIV cure study in humanized mice - (07/25/23)   Cisgender women in seven African countries prefer long-acting injectable to daily oral PrEP for HIV prevention - (07/25/23)   Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease: low statin 44% & anti-hypertensives 39% use among eligible - poor control of risk factors. - (07/25/23)   Early outcomes of successful integration of mental health screening into routine HIV care in Malawi - (07/25/23)   Sleep disorder diagnoses in people with versus without HIV infection in an integrated healthcare system: Insomnia Most Common. PWH More Likely to have Sleep Disorder by 32%. - (07/25/23)   Depressive symptoms and metabolic syndrome among people living with and without HIV in urban Zambia and Zimbabwe - (07/25/23)   Estimating HIV incidence in the era of long-acting PrEP - (07/25/23)   Experience with Using Recency Assay to estimate HIV Incidence in an HIV Prevention Trial - (07/25/23)   Experience with using a registrational cohort to estimate HIV incidence: Lessons from PREPVAcc - (07/25/23)   Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States - (07/25/23)   Starting ART Within 7 Days of Diagnosis Cuts Mortality in Thailand - Mark Mascolini - (07/25/23)   Perceptions of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) From People Living With HIV (PLHIV) in the CARLOS Study - (07/25/23)   Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/25/23)   Participant-Reported Outcomes With Long-Acting Lenacapavir-Based Regimens Among Heavily Treatment-Experienced People Living With HIV in the CAPELLA Clinical Trial - (07/25/23)   Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV - (07/25/23)   Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/25/23)   Each Higher Sedative Burden Unit Boosts Odds of Physical Frailty With HIV 35% - Mark Mascolini - (07/24/23)   STIs Tied to Higher Risk of New HCV Infection in Gay and Bisexual Men - Mark Mascolini - (07/24/23)   ViiV HEALTHCARE'S CABOTEGRAVIR FOR HIV PREVENTION RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY - (07/24/23)   New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic Press Releases - (07/24/23)   DOR/ISL (100/0.75 MG) QD COMPARED TO B/F/TAF AS INITIAL HIV-1 TREATMENT: 48 WEEK RESULTS FROM A DOUBLE-BLIND PHASE 3 TRIAL - (07/24/23)   IAS: ACTG Announces Publication of REPRIEVE Trial in New England Journal of Medicine and Presentation at IAS 2023 - (07/24/23)   IAS: REPRIEVE Results published: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (07/24/23)